Important Heart Alert: Why History of Heart Attack Precludes Evenity Use

Important Heart Alert: Why History of Heart Attack Precludes Evenity Use

Evenity (romosozumab-aqqg) is a powerful osteoporosis treatment, but it carries a serious cardiovascular black box warning from the U.S. Food and Drug Administration (FDA). If you’ve ever had a heart attack, Evenity isn’t right for you. Here’s what you need to know about romosozumab’s safety profile and why a history of heart attack precludes its use.

---

What Is Evenity (Romosozumab)?

Romosozumab is a monoclonal antibody that:

• Stimulates bone formation by inhibiting sclerostin, a protein that slows bone growth
• Reduces bone breakdown by indirectly activating osteoblasts (bone-building cells)
• Is given as two injections (one dose of 210 mg once monthly) for up to 12 months

It’s approved for postmenopausal women at high risk of fracture. In clinical trials, Evenity significantly increased bone density and lowered fracture rates compared to placebo or standard treatments.

---

The Cardiovascular Black Box Warning

Romosozumab’s label includes a black box warning, the FDA’s strongest caution. This warning highlights:

• An increased risk of serious cardiovascular (CV) events—heart attack, stroke, and CV death—seen in one pivotal trial
• A clear contraindication: Evenity must not be used in patients with a heart attack or stroke within the previous year

Why such a strong warning? Let’s look at the evidence.

---

Clinical Trial Findings: ARCH vs. FRAME

Two major trials evaluated romosozumab’s benefits and risks:

1. FRAME (Fracture Study in Postmenopausal Women with Osteoporosis)

   • Compared Evenity to placebo
   • Showed significant fracture reduction
   • Did not show a statistically significant rise in CV events

2. ARCH (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk)

   • Compared Evenity to alendronate (a standard bisphosphonate)
   • Demonstrated superior fracture protection with Evenity
   • Revealed more heart attacks, strokes, and CV deaths in the Evenity group

Key ARCH findings:

• Heart attack or stroke in 2.5% of Evenity patients vs. 1.9% of alendronate patients over 12 months
• CV deaths were also slightly higher with Evenity

Although the absolute difference was small, regulators judged it significant enough to issue a black box warning.

---

Why a History of Heart Attack Precludes Evenity Use

Evenity’s black box warning explicitly states that it’s contraindicated in anyone who has had:

• A myocardial infarction (heart attack) within the previous 12 months
• A stroke within the previous 12 months

Why the strict rule?

• Patients recovering from a heart attack are already at elevated risk for repeat events
• Adding a drug with any signal of increased CV risk could tip the balance toward harm
• Until we fully understand the mechanism—possibly related to sclerostin’s role in blood vessels—regulators mandate avoiding Evenity in these high‐risk individuals

In short, the safety data simply don’t support using romosozumab in anyone recently recovering from a major cardiovascular event.

---

Safety Precautions and Monitoring

If you and your doctor decide Evenity is appropriate, here’s what to watch:

• Baseline CV assessment
– Check blood pressure, lipids, and history of heart disease
• Ongoing monitoring
– Report any chest pain, shortness of breath, or sudden weakness right away
• Limited treatment duration
– Evenity is approved for just 12 months due to long‐term safety unknowns

Your healthcare provider should weigh fracture risk vs. CV risk at every step.

---

Alternative Osteoporosis Treatments

If you’ve had a heart attack—or you’d rather avoid Evenity’s CV questions—several proven options exist:

• Bisphosphonates (alendronate, risedronate, zoledronic acid)
– Decades of safety data
– Low CV risk profile
• Denosumab (Prolia)
– Monoclonal antibody that lowers bone breakdown
– No major CV warning
• Selective estrogen receptor modulators (raloxifene)
– Beneficial for some women, plus positive effects on cholesterol
• Hormone replacement therapy
– Consider in younger postmenopausal women at low CV risk

Discuss these with your doctor to tailor treatment to your overall health picture.

---

Stay Informed and Proactive

Managing osteoporosis safely means balancing fracture prevention with overall health. If you experience any warning signs—new chest pain, sudden numbness, severe headache—don’t wait. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to decide if you need urgent care or a doctor’s appointment.

---

When to Speak to a Doctor

Evenity can be a game-changer for bone health, but it’s not for everyone. If you:

• Have a history of heart attack or stroke
• Are concerned about cardiovascular safety
• Experience any serious symptoms

…reach out to your healthcare provider immediately. Always discuss potential life-threatening or serious conditions with a qualified doctor.

---

Bottom Line: Romosozumab (Evenity) offers strong fracture protection but comes with a cardiovascular black box warning. A history of heart attack within the past year is a clear contraindication. Talk openly with your doctor about your heart and bone health—and consider safer alternatives if CV risk is high. If symptoms arise, act fast: perform a free, online symptom check, using the doctor approved Ubie Symptom Checker and speak to a doctor about any worrying signs.